acquisitions Archives - Vista Partners LLC

Cherry Coke, Cash, and Cul‑de‑Sacs: Inside Berkshire’s Taylor Morrison $6.8B Move -( $BRK.A $BRK.B $TMHC )

by John F. Heerdink, Jr. June 1, 2026 243Views 0Likes

Berkshire Hathaway’s move to buy Taylor Morrison Home is the kind of quietly bold bet that makes long‑only portfolio managers sit up a little straighter and check their housing exposure—again. It is also a reminder that even after Warren Buffett’s transition, Omaha…

Autodesk’s $3.6 Billion Wrench Turn: Why Wall Street Suddenly Loves Maintenance -( $ADSK $AMWL $FMC )

by John F. Heerdink, Jr. May 29, 2026 274Views 0Likes

Autodesk Inc. (NASDAQ: ADSK) just did something very on-brand for the AI era: it paid $3.6 billion in cash for a company that helps factories keep the lights on and the machines behaving. MaintainX, a modern maintenance and operations platform, is Autodesk’s…

Healthcare With Altitude: PACS Delivers, and Salt Lake City Joins the Big‑Cap Conversation -( $PACS )

by John F. Heerdink, Jr. May 12, 2026 347Views 0Likes

PACS Group, Inc. is giving Wall Street a reason to smile, with its Salt Lake City roots, NYSE ticker PACS, and a stock that is rallying smartly today while still showing solid gains over the year despite bouts of volatility. From the Wasatch…

GameStop’s $56 Billion eBay Play: Ryan Cohen Bets Big, Talks Small -( $AMZN $GME $EBAY )

by John F. Heerdink, Jr. May 4, 2026 258Views 0Likes

GameStop (GME) is trying on a new costume: from mall-based meme stock to would‑be e‑commerce juggernaut. The company has lobbed a roughly $55–56 billion cash‑and‑stock offer for eBay (EBAY), proposing $125 per share, a premium to where eBay traded before the news hit.…

Eli Lilly’s Strategic Shopping Spree Signals a New Era in Biotech Consolidation -( $LLY $XBI $IBB )

by John F. Heerdink, Jr. April 29, 2026 214Views 0Likes

In a market where capital efficiency has become the new currency of credibility, Eli Lilly & Co. (LLY) appears to be writing a decidedly modern playbook for growth—one acquisition at a time. The Indianapolis-based pharmaceutical heavyweight has quietly assembled a portfolio of…

Amazon’s $11.6B Globalstar Acquisition: A Signal That the Sky’s No Longer the Limit -( $AAPL $AMZN $GSAT )

by John F. Heerdink, Jr. April 14, 2026 271Views 0Likes

In a move that underscores the convergence of cloud, communications, and capital, Amazon (NASDAQ: AMZN) confirmed plans to acquire Globalstar (NYSE: GSAT) in an $11.6 billion all-cash deal. The acquisition represents Amazon’s most assertive step yet into the satellite communications sector, fortifying its ambitions to extend Project…

Chasing Vibes or Buying an AI Moat? OpenAI’s ‘Tech bros’ TBPN Deal Explained

by John F. Heerdink, Jr. April 3, 2026 185Views 0Likes

OpenAI’s purchase of TBPN turns a buzzy tech talk show into a strategic asset, and in the process makes the company look less like a lab and more like a network—in every sense of the word. The deal may read as “chasing…

Acquired Taste: Why Big Pharma Can’t Stop Snacking on Venture‑Backed Biotechs -( $IBB $MRK $OTSKY $NVS $TERN $XBI )

by John F. Heerdink, Jr. April 2, 2026 335Views 0Likes

Big Pharma spent the week shopping again, snapping up a fresh crop of biotech and pharmaceutical names in deals that underscore one message: pipelines are the new gold, and the majors are still happily paying spot prices. From autoimmune bets to allergy…

Is NAYA Therapeutics the Next Radiopharma Takeout? The Pipeline, the Board, and the Buzz – ( $AZN $BMY $IBB $LLY $NVS $XBI )

by John F. Heerdink, Jr. March 18, 2026 360Views 0Likes

NAYA Therapeutics (https://www.nayatx.com) is quietly trying to make “next‑gen radiopharma” sound less like sci‑fi and more like standard operating procedure—and its new board lineup reads like a who’s who of oncology, nuclear medicine, and biotech capital markets. A New Board for a…

Servier’s $2.5 Billion Bet on Rare Oncology: A Strategic Day One Biopharmaceuticals Play With a Pediatric Pulse -( $DAWN $XBI $IBB )

by John F. Heerdink, Jr. March 6, 2026 1032Views 0Likes

French pharmaceutical group Servier has quietly become one of the most methodical players in oncology—and its latest move underscores that reputation. The company announced a definitive agreement to acquire Day One Biopharmaceuticals (Nasdaq: DAWN) for $21.50 per share in cash, valuing the…

Tag: acquisitions

Cherry Coke, Cash, and Cul‑de‑Sacs: Inside Berkshire’s Taylor Morrison $6.8B Move -( $BRK.A $BRK.B $TMHC )

Autodesk’s $3.6 Billion Wrench Turn: Why Wall Street Suddenly Loves Maintenance -( $ADSK $AMWL $FMC )

Healthcare With Altitude: PACS Delivers, and Salt Lake City Joins the Big‑Cap Conversation -( $PACS )

GameStop’s $56 Billion eBay Play: Ryan Cohen Bets Big, Talks Small -( $AMZN $GME $EBAY )

Eli Lilly’s Strategic Shopping Spree Signals a New Era in Biotech Consolidation -( $LLY $XBI $IBB )

Amazon’s $11.6B Globalstar Acquisition: A Signal That the Sky’s No Longer the Limit -( $AAPL $AMZN $GSAT )

Chasing Vibes or Buying an AI Moat? OpenAI’s ‘Tech bros’ TBPN Deal Explained

Acquired Taste: Why Big Pharma Can’t Stop Snacking on Venture‑Backed Biotechs -( $IBB $MRK $OTSKY $NVS $TERN $XBI )

Is NAYA Therapeutics the Next Radiopharma Takeout? The Pipeline, the Board, and the Buzz – ( $AZN $BMY $IBB $LLY $NVS $XBI )

Servier’s $2.5 Billion Bet on Rare Oncology: A Strategic Day One Biopharmaceuticals Play With a Pediatric Pulse -( $DAWN $XBI $IBB )

Your Guide To Staying Informed In The Markets